Jefferies Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jefferies Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.46M	Sell	31,002 -424,343	-93%	-$35.8M	0.02%	535
2022 Q2	$33.8M	Sell	455,345 -273,672	-38%	-$20.5M	0.28%	59
2022 Q1	$65.5M	Buy	729,017 +665,200	+1,042%	+$61.4M	0.41%	31
2021 Q4	$7.14M	Sell	63,817 -266,433	-81%	-$32.1M	0.04%	358
2021 Q3	$41.5M	Hold	330,250	–	–	0.3%	48
2021 Q2	$44.7M	Sell	330,250 -144,250	-30%	-$19M	0.28%	53
2021 Q1	$64.4M	Buy	474,500 +414,500	+691%	+$62.1M	0.56%	24
2020 Q4	$8.45M	Sell	60,000 -58,005	-49%	-$7.43M	0.07%	258
2020 Q3	$13.1M	Sell	118,005 -73,798	-38%	-$8.27M	0.15%	100
2020 Q2	$21.5K	Buy	191,803 +77,706	+68%	+$7.65M	0.25%	47
2020 Q1	$8.84M	Buy	114,097 +65,443	+135%	+$5.79M	0.1%	176
2019 Q4	$4.63M	Sell	48,654 -142,335	-75%	-$12.3M	0.04%	554
2019 Q3	$14.6M	Buy	190,989 +86,809	+83%	+$7.21M	0.11%	124
2019 Q2	$9.14M	Buy	104,180 +52,000	+100%	+$4.44M	0.07%	252
2019 Q1	$4.72M	Sell	52,180 -27,575	-35%	-$2.35M	0.04%	463
2018 Q4	$5.72M	Sell	79,755 -22,425	-22%	-$1.81M	0.05%	366
2018 Q3	$9.8M	Buy	102,180 +100,000	+4,587%	+$9.7M	0.06%	280
2018 Q2	$208K	Sell	2,180 -900	-29%	-$82.7K	﹤0.01%	2022
2018 Q1	$270K	Buy	3,080 +900	+41%	+$82.2K	﹤0.01%	1846
2017 Q4	$185K	Sell	2,180 -800	-27%	-$67K	﹤0.01%	2242
2017 Q3	$258K	Sell	2,980 -31,500	-91%	-$2.53M	﹤0.01%	1954
2017 Q2	$2.66M	Buy	34,480 +32,300	+1,482%	+$2.29M	0.02%	820
2017 Q1	$151K	Sell	2,180 -75,698	-97%	-$5.08M	﹤0.01%	2087
2016 Q4	$4.61M	Buy	77,878 +76,728	+6,672%	+$4.74M	0.03%	595
2016 Q3	$76K	Sell	1,150 -81,715	-99%	-$5.06M	﹤0.01%	2060
2016 Q2	$4.48M	Sell	82,865 -12,390	-13%	-$679K	0.02%	529
2016 Q1	$4.92M	Buy	95,255 +94,505	+12,601%	+$4.91M	0.03%	489
2015 Q4	$53K	Sell	750 -46,540	-98%	-$3.17M	﹤0.01%	2120
2015 Q3	$2.94M	Buy	47,290 +46,540	+6,205%	+$3.67M	0.02%	717
2015 Q2	$63K	Buy	+750	New	+$58.3K	﹤0.01%	2360
2014 Q4	–	Sell	-750	Closed	-$42.8K	–	2384
2014 Q3	$39K	Buy	+750	New	+$38.2K	﹤0.01%	2003

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jefferies Group's XBI Position: Q3 2022 in Review

Jefferies Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 93% in Q3 2022, selling an estimated $35.8M and leaving 31,002 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #535.

Jefferies Group first reported a position in XBI in Q3 2014 and has held it in 31 quarters since. The position peaked at $65.5M in Q1 2022. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Jefferies Group held 31,002 shares of State Street SPDR S&P Biotech ETF worth $2.46M as of Q3 2022.
Jefferies Group sold 424,343 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $35.8M.
State Street SPDR S&P Biotech ETF made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #535 holding.
Jefferies Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2014 and has held it in 31 quarters since.
Jefferies Group's State Street SPDR S&P Biotech ETF position peaked at $65.5M in Q1 2022.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.